BioAtla, Inc. (BCAB)
BCAB Stock Price Chart
Explore BioAtla, Inc. interactive price chart. Choose custom timeframes to analyze BCAB price movements and trends.
BCAB Company Profile
Discover essential business fundamentals and corporate details for BioAtla, Inc. (BCAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Dec 2020
Employees
61.00
Website
https://www.bioatla.comCEO
Jay M. Short
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB Financial Timeline
Browse a chronological timeline of BioAtla, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.31.
Earnings released on 7 Aug 2025
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%.
Earnings released on 6 May 2025
EPS came in at -$0.29 falling short of the estimated -$0.28 by -3.57%.
Earnings released on 27 Mar 2025
EPS came in at -$0.32 surpassing the estimated -$0.40 by +20.00%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.34 by +35.29%, while revenue for the quarter reached $11.00M .
Earnings released on 8 Aug 2024
EPS came in at -$0.44 surpassing the estimated -$0.45 by +2.22%.
Earnings released on 14 May 2024
EPS came in at -$0.48 surpassing the estimated -$0.57 by +15.79%.
Earnings released on 26 Mar 2024
EPS came in at -$0.56 surpassing the estimated -$0.79 by +29.11%, while revenue for the quarter reached $1.71M .
Earnings released on 7 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.77 by +9.09%.
Earnings released on 1 Aug 2023
EPS came in at -$0.75 falling short of the estimated -$0.64 by -17.19%.
Earnings released on 11 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.66 by +12.12%.
Earnings released on 23 Mar 2023
EPS came in at -$0.63 surpassing the estimated -$0.74 by +14.86%.
Earnings released on 4 Nov 2022
EPS came in at -$0.69 surpassing the estimated -$0.77 by +10.39%.
Earnings released on 9 Aug 2022
EPS came in at -$0.77 falling short of the estimated -$0.70 by -10.00%.
Earnings released on 5 May 2022
EPS came in at -$0.65 surpassing the estimated -$0.69 by +5.80%.
Earnings released on 1 Mar 2022
EPS came in at -$0.63 surpassing the estimated -$0.72 by +12.50%, while revenue for the quarter reached $250.00K , missing expectations by -94.57%.
Earnings released on 15 Nov 2021
EPS came in at -$0.68 surpassing the estimated -$0.92 by +26.09%, while revenue for the quarter reached $150.00K , missing expectations by -96.74%.
Earnings released on 13 Aug 2021
EPS came in at -$0.90 falling short of the estimated -$0.56 by -60.71%, while revenue for the quarter reached $250.00K , beating expectations by +2.85%.
Earnings released on 12 May 2021
EPS came in at -$0.56 falling short of the estimated -$0.52 by -7.69%.
Earnings released on 25 Mar 2021
EPS came in at -$1.50 falling short of the estimated -$0.78 by -92.31%, while revenue for the quarter reached $0.00 .
Earnings released on 17 Dec 2020
EPS came in at -$0.29 , while revenue for the quarter reached $190.00K .
Earnings released on 30 Sept 2020
EPS came in at -$0.38 , while revenue for the quarter reached $150.00K .
BCAB Stock Performance
Access detailed BCAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.